About this Research Topic
This Research Topic is part of a series with:
Targeted Cancer Therapies, from Small Molecules to Antibodies, Volume II
Cancer is the second leading cause of death due to its high morbidity and mortality. Cytotoxic drugs have brought great success in treating cancer, but the cytotoxic effects can also affect other normal cells in the body that lead to serious side effects. The development of novel antitumor therapeutics is a lasting topic and keeps up with the times, particularly the development of new chemotherapy and targeted therapy.
Targeted therapy differs from traditional chemotherapy as it targets specific genes or proteins found in cancer cells that make them different from normal cells. Those specific genes or proteins are often involved in the growth, progression, and metastasis of cancer. Therefore, targeted therapy provided a more accurate treatment option in which patients receive drugs targeted on specific molecular targets that are associated with cancer. While the side effects of targeted therapies are much fewer than those of standard chemotherapy, targeted therapies are currently the focus of much anticancer drug development, and identification of drug targets is a key step in the development of effective therapeutic agents. There are 2 major types of targeted therapy; small molecular drugs and monoclonal antibodies. With more targets identified in recent years, targeted therapy began a new era for treating cancer with promising hope. Notable examples in recently approved targeted therapies include imatinib targeting bcr-abl, gefitinib targeting EFGR, ceritinib targeting ALK, anti-PD-1 monoclonal antibody nivolumab, anti-EGFR monoclonal antibody cetuximab, and anti-HER2 monoclonal antibody trastuzumab.
Our goal is to promote communication and exchange of information through publication of important manuscripts. This Research Topic aims to publish full-length articles regarding basic and translational research in the discovery of novel targets and targeting anticancer agents including small molecules or macromolecules such as antibodies. We will include timely reviews covering the broad scope of cancer-targeting drugs including but not limited to hormone therapies, signal transduction inhibitors, apoptosis inducers, angiogenesis inhibitors, immunotherapies and monoclonal antibodies that deliver toxic molecules. Furthermore, we hope that through this Research Topic we will be able to find some articles which cover the new targets for future potential therapeutics and development of new technology.
Targeted Cancer Therapies, from Small Molecules to Antibodies, Volume II
Cancer is the second leading cause of death due to its high morbidity and mortality. Cytotoxic drugs have brought great success in treating cancer, but the cytotoxic effects can also affect other normal cells in the body that lead to serious side effects. The development of novel antitumor therapeutics is a lasting topic and keeps up with the times, particularly the development of new chemotherapy and targeted therapy.
Targeted therapy differs from traditional chemotherapy as it targets specific genes or proteins found in cancer cells that make them different from normal cells. Those specific genes or proteins are often involved in the growth, progression, and metastasis of cancer. Therefore, targeted therapy provided a more accurate treatment option in which patients receive drugs targeted on specific molecular targets that are associated with cancer. While the side effects of targeted therapies are much fewer than those of standard chemotherapy, targeted therapies are currently the focus of much anticancer drug development, and identification of drug targets is a key step in the development of effective therapeutic agents. There are 2 major types of targeted therapy; small molecular drugs and monoclonal antibodies. With more targets identified in recent years, targeted therapy began a new era for treating cancer with promising hope. Notable examples in recently approved targeted therapies include imatinib targeting bcr-abl, gefitinib targeting EFGR, ceritinib targeting ALK, anti-PD-1 monoclonal antibody nivolumab, anti-EGFR monoclonal antibody cetuximab, and anti-HER2 monoclonal antibody trastuzumab.
Our goal is to promote communication and exchange of information through publication of important manuscripts. This Research Topic aims to publish full-length articles regarding basic and translational research in the discovery of novel targets and targeting anticancer agents including small molecules or macromolecules such as antibodies. We will include timely reviews covering the broad scope of cancer-targeting drugs including but not limited to hormone therapies, signal transduction inhibitors, apoptosis inducers, angiogenesis inhibitors, immunotherapies and monoclonal antibodies that deliver toxic molecules. Furthermore, we hope that through this Research Topic we will be able to find some articles which cover the new targets for future potential therapeutics and development of new technology.
Keywords: Cancer, Target, Small Molecules, Antibodies, Therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
